Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna (MRNA) announced the FDA has extended emergency use authorization for its COVID-19 vaccine booster at a 50 µg dose for all adults aged 18 and older. This decision allows the booster to be administered to individuals who completed primary vaccination with any approved COVID-19 vaccine. The authorization is seen as critical due to rising COVID-19 cases. The FDA's decision was based on data from a Phase 2 study indicating a significant immune response from the booster dose. The CDC will meet to discuss rollout recommendations.
Moderna has initiated a Phase 2/3 clinical trial for its RSV vaccine candidate, mRNA-1345, with plans to enroll approximately 34,000 participants across multiple countries.
RSV is responsible for significant health issues in older adults and young children but currently lacks an approved vaccine. The Company reports an estimated $3 billion annual medical cost due to RSV in the U.S., with about 177,000 hospitalizations and 14,000 deaths among adults 65 and older annually. The trial aims to evaluate the safety and efficacy of mRNA-1345 in adults over 60, supporting future licensure efforts.
Moderna Inc. (Nasdaq: MRNA) has submitted a request for authorization to Health Canada for a 50 µg two-dose series of its COVID-19 vaccine, SPIKEVAX, aimed at children aged 6 to 11. The ongoing Phase 2/3 ‘KidCOVE’ study reports a vaccine efficacy of 100% against symptomatic COVID-19 and 80% for any SARS-CoV-2 infection post-first dose. The firm plans to share these findings with global regulatory bodies to ensure broader protection for this vulnerable age group.
Moderna has received authorization from Health Canada for a booster dose of its COVID-19 vaccine, SPIKEVAX, at a 50 µg dose for individuals aged 18 and older, to be given at least six months after the primary series.
The decision was based on clinical data indicating significant increases in neutralizing antibody levels post-booster, including in adults over 65. The safety profile aligns with previous doses, establishing confidence in the vaccine's continued efficacy against variants.
Moderna announced positive results from the Phase 2 EPICCURE study assessing AZD8601, an mRNA therapeutic for patients undergoing coronary artery bypass grafting (CABG). The study met its primary endpoint of safety and tolerability with 11 participants, revealing numerical improvements in heart failure endpoints, including increased left ventricular ejection fraction (LVEF). All treated patients maintained healthy NT-proBNP levels at follow-up. This data reinforces the potential of AZD8601 for advancing treatment options in heart failure and warrants further exploration in larger studies.
Moderna (MRNA) announced interim data from a Phase 1 study of mRNA-2752 for treating solid tumors and lymphomas, demonstrating tolerability at all doses tested. The combination therapy with durvalumab (IMFINZI®) showed encouraging anti-tumor activity, with a recommended dose for expansion set at 8mg. Presenting at the Society for Immunotherapy of Cancer's Annual Meeting, the study indicated immunomodulation effects, including increased T cell activation. Ongoing trials continue for various cancers, showcasing the potential of Moderna’s innovative mRNA platform in oncology.
Moderna (Nasdaq: MRNA) has submitted a variation for conditional marketing authorization of its COVID-19 vaccine (mRNA-1273) for children aged 6 to 11 years to the European Medicines Agency (EMA). This marks Moderna's first submission for this age group. The ongoing Phase 2/3 KidCOVE study has shown vaccine efficacy of 100% for symptomatic COVID-19 and 80% for all SARS-CoV-2 infections after the first dose. The company plans to share data with various regulatory agencies globally to protect younger populations.
Moderna reported a robust Q3 2021 with total revenue of $5.0 billion, a significant increase from $157 million in Q3 2020. The net income surged to $3.3 billion, resulting in diluted EPS of $7.70. Key developments include the U.S. FDA granting Priority Review for the COVID-19 vaccine BLA and promising interim efficacy results from the KidCOVE study showing 100% effectiveness after the first dose in kids aged 6-12. Moderna also initiated a Phase 3 study for a CMV vaccine and unveiled plans for inhaled pulmonary therapeutics with Vertex.
